Stonebridge Capital Advisors’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Stonebridge Capital Advisors’s Portfolio PLXP Stock Details PLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,250	Closed	-$95K	–	163
2016 Q1	$95K	Buy	+1,250	New	+$79.5K	0.03%	144

Other funds holding PLXP

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Lone Star Value Management Old Greenwich, Connecticut $52.7M AUM 30.18% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Emerald Acquisition Seattle, Washington $51.8B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Timpani Capital Management Milwaukee, Wisconsin $209M AUM 62.15% 1-Year Est. Return

Stonebridge Capital Advisors's PLXP Position: Q2 2016 in Review

Stonebridge Capital Advisors sold out of PLx Pharma Inc. Common Stock (PLXP) in Q2 2016, closing a stake of 1,250 shares — an estimated $95K sold.

Stonebridge Capital Advisors first reported a position in PLXP in Q1 2016 and held it in 1 quarter. The position peaked at $95K in Q1 2016. 33 funds tracked by Wall St. Rank hold PLXP as of Q2 2016.

Stonebridge Capital Advisors reported no remaining PLx Pharma Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
Stonebridge Capital Advisors sold 1,250 PLx Pharma Inc. Common Stock shares in Q2 2016, an estimated $95K.
Stonebridge Capital Advisors first reported a position in PLx Pharma Inc. Common Stock in Q1 2016 and held it in 1 quarter.
Stonebridge Capital Advisors's PLx Pharma Inc. Common Stock position peaked at $95K in Q1 2016.
33 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q2 2016.

Based on Stonebridge Capital Advisors's 13F filing for Q2 2016, filed 16 Aug 2016.